Published in Eur J Cancer on September 01, 2001
A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma. J Gastrointest Oncol (2011) 0.77
Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. Cancer Chemother Pharmacol (2016) 0.75
Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. World J Gastroenterol (2015) 0.75
Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer. Gastric Cancer (2010) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res (2001) 4.05
Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med (1999) 3.20
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst (2009) 2.83
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst (2000) 2.73
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol (2000) 2.60
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer (2002) 2.34
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res (1999) 2.00
Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br J Cancer (1999) 1.96
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol (2001) 1.77
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol (2001) 1.70
Conserving large populations of lions - the argument for fences has holes. Ecol Lett (2013) 1.69
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer (2001) 1.65
Rabies in African wild dogs (Lycaon pictus) in the Serengeti region, Tanzania. J Wildl Dis (1993) 1.65
Inhibition of the G1-S transition of the cell cycle by inhibitors of deoxyhypusine hydroxylation. Biochim Biophys Acta (1994) 1.62
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Ann Oncol (2002) 1.52
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer (1998) 1.51
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1995) 1.49
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J Clin Oncol (1999) 1.48
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol (2003) 1.48
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer (1999) 1.45
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol (2008) 1.44
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer (2012) 1.38
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol (2001) 1.38
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol (2005) 1.33
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood (1998) 1.32
Immunoscintigraphy of colon carcinoma. J Nucl Med (1984) 1.31
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) Br J Cancer (1994) 1.30
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res (2001) 1.29
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer (2003) 1.25
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 1.25
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer (2003) 1.24
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs (2001) 1.22
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res (2000) 1.21
Detection of a sub-set of polysomal mRNAs associated with modulation of hypusine formation at the G1-S boundary. Proposal of a role for eIF-5A in onset of DNA replication. FEBS Lett (1995) 1.21
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer (2003) 1.21
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos (2001) 1.20
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol (2009) 1.20
Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs (2001) 1.16
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst (1992) 1.16
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol (2010) 1.14
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer (2011) 1.14
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet (2001) 1.12
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res (1999) 1.12
Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol (2000) 1.12
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol (2003) 1.10
In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer (1998) 1.09
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.09
Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol (2001) 1.08
Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol (2012) 1.08
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol (2002) 1.07
Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology (2001) 1.07
Coping with toxicities of docetaxel (Taxotere). Ann Oncol (1993) 1.06
Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet (1998) 1.06
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. Br J Cancer (2012) 1.06
Antiretroviral effects of deoxyhypusyl hydroxylase inhibitors: a hypusine-dependent host cell mechanism for replication of human immunodeficiency virus type 1 (HIV-1). Biochem Pharmacol (1998) 1.05
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer (1994) 1.05
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol (2011) 1.03
Aspects of rabies infection and control in the conservation of the African wild dog (Lycaon pictus) in the Serengeti region, Tanzania. Onderstepoort J Vet Res (1993) 1.02
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol (2004) 1.01
Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. Clin Cancer Res (1997) 1.01
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. Rev Neurol (Paris) (2008) 1.01
Immunoscintigraphy of recurrences of gynecologic carcinomas. J Nucl Med (1987) 1.01
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol (1998) 1.01
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol (2011) 1.00
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Br J Cancer (2005) 1.00
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer (2001) 0.99
Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane. Invest New Drugs (1996) 0.99
Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol (2012) 0.99
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer (1997) 0.98
Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs (1994) 0.97
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol (1999) 0.97
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol (1997) 0.96
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res (2000) 0.96
Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer (1994) 0.96
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. Br J Cancer (2001) 0.96
G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. Br J Cancer (2004) 0.96
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer (2003) 0.95
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol (1995) 0.95
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer (2002) 0.95
Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet (2000) 0.95
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer (1999) 0.95